Hims & Hers Health, Inc. (HIMS) Announced Q1 2026 Earnings on May 11, 2026, Reporting "In the first quarter, revenue grew 4% year-over-year to $608 million"

Hims & Hers Health, Inc. reported first quarter 2026 revenue of $608 million, representing a 4% year-over-year growth rate.Subscribers grew 9% year-over-year to nearly 2.6 million.First quarter adjusted EBITDA was $44 million, representing a 7% adjusted EBITDA margin, while GAAP net income declined to a loss of $92 million due to restructuring, M&A, and legal costs.The company generated $89 million in cash flow from operations and $53 million in free cash flow, ending the quarter with $751 million in available cash and short-term investments.First quarter gross margins were 65% on a GAAP basis, impacted by restructuring costs related to a strategic pivot in the weight loss specialty.Management highlighted a strategic shift to prioritize branded products within its weight loss business, which expanded direct access to Novo Nordisk GLP-1 products like Wegovy.Following this launch, the company is on track to add north of 100,000 new subscribers per month within the weight loss specialty.The company also saw momentum in newer specialties like testosterone, menopause, and labs.Furthermore, the company is integrating AI capabilities across its platform, launching Labs AI and an AI copilot for providers, and is actively preparing to enter the peptide therapies category.On the partnership and M&A front, the company collaborated with Novo Nordisk and completed the acquisition of YourBio to bring painless at-home blood collection technology to its platform.Hims & Hers also expects its planned acquisition of Eucalyptus to close in the second half of the year, extending its consumer health leadership into Australia, the U.K., Germany, Japan, and Canada.For the second quarter of 2026, the company anticipates revenue in the range of $680 million to $700 million and adjusted EBITDA between $35 million to $55 million.For the full year 2026, management raised its revenue outlook to $2.8 billion to $3 billion and expects adjusted EBITDA to be between $275 million and $350 million.These guidance figures do not include the pending Eucalyptus transaction.